FDA is to assess data linking type 2 diabetes drugs with pancreatitis

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f1808 (Published 19 March 2013)
Cite this as: BMJ 2013;346:f1808

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Deborah Cohen
  1. 1BMJ

The US Food and Drug Administration has taken the unusual stance of announcing that it will evaluate data provided to it by a group of unnamed independent researchers indicating that glucagon-like peptide-1 (GLP-1) based drugs used in type 2 diabetes could raise the risk of pancreatitis and precancerous pancreatic lesions.

According to the FDA’s statement the data indicate an increased risk of pancreatitis and cellular changes called pancreatic duct metaplasia in people with type 2 diabetes who are treated with the drugs, which are incretin mimetics.1 However, the FDA emphasized that it has not reached any new conclusions about the safety of the drugs, nor has it “concluded …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL